CAR-macrophages
Construct PatternCARmacrophages (CAR-M) ... not only phagocytose tumor cells and present antigens but also remodel the immunosuppressive tumor microenvironment
Browse the toolkit beneath workflows. The mechanism branch runs mechanism -> architecture -> component, while the technique branch runs from high-level approaches down to concrete methods.
6 items matching 1 filter
Mechanism Branch
Layer 1
Mechanisms
Top-level concepts: biophysical action modes such as heterodimerization, photocleavage, or RNA binding.
Layer 2
Architectures
Arrangements that realize or deploy mechanisms, including switches, construct patterns, and delivery strategies.
Layer 3
Components
Low-level parts and sequence-defined elements used inside architectures, including protein domains and RNA elements.
Technique Branch
Layer 1
Approaches
High-level engineering practices such as computational design, directed evolution, sequence verification, and functional assay.
Layer 2
Methods
Concrete methods used to design, build, verify, or characterize engineered systems.
Showing 1-6 of 6
CARmacrophages (CAR-M) ... not only phagocytose tumor cells and present antigens but also remodel the immunosuppressive tumor microenvironment
We produced and verified a novel virus-like particle (VLP) by incorporating the neutralizing epitope 1134SVQSFDGKL1142 into a recombinant hepatitis B virus core antigen (HBcAg) scaffold.
Engineering chimeric antigen receptors (CARs) to endow macrophages with anti-tumor capacities demonstrated encouraging efficacy, particularly in enhancing tumor-targeted phagocytosis. Furthermore, CAR macrophages (CAR-Ms) orchestrate adaptive immunity through secreting pro-inflammatory cytokines and presenting tumor antigens, thereby activating cytotoxic T lymphocyte responses.
sophisticated logic-gated circuits
Recently, CAR-macrophage (CAR-M) immunotherapy has emerged as a promising strategy to overcome these barriers.
This review summarizes current evidence on mRNA melanoma vaccines, focusing on two leading delivery platforms: lipid nanoparticles (LNPs) and dendritic cell (DC) vaccines.